Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Degarelix (trade name Firmagon) is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike GnRH agonists, it blocks the receptor directly and does not trigger an initial testosterone surge (flare). It is an approved prescription medicine for the treatment of advanced, hormone-dependent prostate cancer. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation.
Researched for
Advanced prostate cancer (androgen deprivation)Rapid testosterone suppression without flareHormone-dependent prostate cancer
Official status
US: Prescription
In the US, approved by the FDA in 2008 as a prescription medicine (Firmagon) for the treatment of advanced prostate cancer. Dispensed on a physician's prescription only.
Degarelix is a competitive GnRH receptor antagonist. It binds reversibly and immediately to the pituitary GnRH receptors and blocks their activation. This rapidly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn lowers testosterone production in the testes. Unlike GnRH agonists (e.g., leuprorelin), which first cause a transient stimulation with a testosterone surge (flare), this direct antagonism lacks the initial stimulation phase, so testosterone declines without a preceding rise. This mechanism underlies the literature-described use in hormone-dependent prostate cancer.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · 2 tiers
Human RCT
3
Human trial
1
03
What the studies show
Human RCT
Mensch
Klotz L et al. 2008
In a randomized phase III study, degarelix lowered testosterone without the initial surge (flare) seen with GnRH agonists and achieved castrate-range suppression over the study year, comparable to leuprorelin.
What does NOT follow: Findings derive from an open-label, controlled study in prostate cancer patients over twelve months and do not transfer to other populations or contexts. No usage inference.
Human RCT
Mensch
Klotz L et al. 2008
In the phase III study, degarelix produced a faster initial decline in testosterone and prostate-specific antigen (PSA) than the agonist comparator arm.
What does NOT follow: A faster PSA decline is a laboratory course parameter and is not equivalent to a proven advantage on hard clinical endpoints. The statement refers to the studied cohort.
Human trial
Mensch
Albertsen PC et al. 2014
In a pooled analysis of several randomized trials, treatment with the GnRH antagonist in men with pre-existing cardiovascular disease was associated with a lower risk of cardiovascular events within one year than treatment with GnRH agonists.
What does NOT follow: This is a retrospective pooled analysis, not a study prospectively powered for cardiovascular endpoints; the association does not prove causation, and later prospective trials have nuanced the picture.
Human RCT
Mensch
Damber JE et al. 2012
The extent and speed of testosterone suppression were also examined as a function of baseline testosterone in a further analysis of the same phase III study.
What does NOT follow: Subgroup and secondary analyses are hypothesis-generating; they were not primarily designed to compare subgroups and permit no usage inference.
04
Where studies disagree
Open question
Does the GnRH antagonist degarelix lower cardiovascular risk compared with GnRH agonists?
POSITION A
A retrospective pooled analysis of several randomized trials found a lower one-year risk of cardiovascular events under the antagonist in men with pre-existing cardiovascular disease.
POSITION B
This analysis was not prospectively designed for cardiovascular endpoints; a later trial prospectively designed for this (PRONOUNCE) could not show a statistically significant difference in cardiovascular risk between antagonist and agonist owing to early termination and a low event count.
CURRENT STATE · The question is considered unresolved: signals from pooled data were not confirmed by the prospective trial; the conclusiveness of both sources is methodologically limited.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 1320 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
In the clinical and pharmacokinetic literature, degarelix is described as a subcutaneous depot that forms a gel depot with sustained release after injection. Purely descriptive, not a usage instruction.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Injection-site reactions (e.g., pain, redness, swelling) were reported more frequently with degarelix than in the agonist comparator arm in the phase III study.
Frequency and severity depend on formulation and population; reported in a controlled study, not a complete safety assessment and no substitute for the official prescribing information.
Human RCT
Consequences of androgen deprivation such as hot flushes and weight gain were described as typical class effects of testosterone suppression.
These effects are general consequences of a low testosterone state and not specific to degarelix; findings derive from controlled studies in the approved indication.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
In prostate-cancer communities, degarelix is often mentioned as an option without the initial testosterone flare compared to the classic GnRH agonists.
recurring in treatment-choice discussions
Not supported by studies: The absence of the flare is a documented pharmacological class difference (antagonist vs. agonist) — a report, not a treatment recommendation.
10b
What online communities discuss
Recurring themes from Reddit, Quora and patient forums — synthetically summarised, sources linked. Not scientific evidence, but a signal of what users report. Deliberately separated from the study base.
Non-scientific sources. What users report in forums — synthetically summarised, paraphrased, with link to source. Not validated by studies.
Sorted by discussion frequency · 1 Thema
Discussion frequency: small base (~10–15 reviews)
On drugs.com, degarelix (Firmagon) is rated highly despite a small base (around 8–9 out of 10 from about 10–15 reviews, predominantly positive). Reported are a marked PSA drop in prostate cancer alongside injection-site pain, hot flashes and fatigue.
What this does NOT mean:Review platforms are self-selected, unblinded and not representative; the figures are a snapshot (as of June 2026). They do not replace controlled data — see the studies section. As a GnRH ANTAGONIST, degarelix lowers testosterone immediately, without the initial flare of the GnRH agonists (leuprolide, goserelin) — a documented mechanistic difference that shapes the reports. With so few reviews, however, the average is not robust.
In the US, approved by the FDA in 2008 as a prescription medicine (Firmagon) for the treatment of advanced prostate cancer. Dispensed on a physician's prescription only.
2026-06-07
Germany
Prescription
In Germany, available under the EU-wide EMA authorisation (marketing authorisation 2009) as a prescription medicine (Firmagon) for the treatment of advanced, hormone-dependent prostate cancer; dispensed by pharmacies on a physician's prescription only.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients